The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Background Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-gro...
Saved in:
Published in | British journal of cancer Vol. 131; no. 10; pp. 1656 - 1667 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
30.11.2024
Nature Publishing Group Springer Nature |
Subjects | |
Online Access | Get full text |
ISSN | 0007-0920 1532-1827 1532-1827 |
DOI | 10.1038/s41416-024-02875-5 |
Cover
Abstract | Background
Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment.
Methods
Bulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500).
Results
Increased activity in signaling pathways involving SRC-family kinases (SFKs)- and MAPK/ERK was found in treatment resistant PDX, with targeted inhibitors being significantly more potent in resistant tumors. Up-regulation of SFKs- and MAPK/ERK-pathways was also detected in a sub-group of chemoresistant patients after neoadjuvant treatment. Furthermore,
High
SFK expression (of either
SRC, FYN
and/or
YES1
) was detected in metastatic lesions of TNBC patients with fast progressing disease (median disease-free interval 27
vs
105 months).
Conclusions
Upregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs. |
---|---|
AbstractList | Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment.BACKGROUNDResistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment.Bulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500).METHODSBulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500).Increased activity in signaling pathways involving SRC-family kinases (SFKs)- and MAPK/ERK was found in treatment resistant PDX, with targeted inhibitors being significantly more potent in resistant tumors. Up-regulation of SFKs- and MAPK/ERK-pathways was also detected in a sub-group of chemoresistant patients after neoadjuvant treatment. Furthermore, High SFK expression (of either SRC, FYN and/or YES1) was detected in metastatic lesions of TNBC patients with fast progressing disease (median disease-free interval 27 vs 105 months).RESULTSIncreased activity in signaling pathways involving SRC-family kinases (SFKs)- and MAPK/ERK was found in treatment resistant PDX, with targeted inhibitors being significantly more potent in resistant tumors. Up-regulation of SFKs- and MAPK/ERK-pathways was also detected in a sub-group of chemoresistant patients after neoadjuvant treatment. Furthermore, High SFK expression (of either SRC, FYN and/or YES1) was detected in metastatic lesions of TNBC patients with fast progressing disease (median disease-free interval 27 vs 105 months).Upregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs.CONCLUSIONSUpregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs. Background Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment. Methods Bulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500). Results Increased activity in signaling pathways involving SRC-family kinases (SFKs)- and MAPK/ERK was found in treatment resistant PDX, with targeted inhibitors being significantly more potent in resistant tumors. Up-regulation of SFKs- and MAPK/ERK-pathways was also detected in a sub-group of chemoresistant patients after neoadjuvant treatment. Furthermore, High SFK expression (of either SRC, FYN and/or YES1 ) was detected in metastatic lesions of TNBC patients with fast progressing disease (median disease-free interval 27 vs 105 months). Conclusions Upregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs. BackgroundResistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment.MethodsBulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500).ResultsIncreased activity in signaling pathways involving SRC-family kinases (SFKs)- and MAPK/ERK was found in treatment resistant PDX, with targeted inhibitors being significantly more potent in resistant tumors. Up-regulation of SFKs- and MAPK/ERK-pathways was also detected in a sub-group of chemoresistant patients after neoadjuvant treatment. Furthermore, High SFK expression (of either SRC, FYN and/or YES1) was detected in metastatic lesions of TNBC patients with fast progressing disease (median disease-free interval 27 vs 105 months).ConclusionsUpregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs. BACKGROUND: Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment. METHODS: Bulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500). RESULTS: Increased activity in signaling pathways involving SRC-family kinases (SFKs)- and MAPK/ERK was found in treatment resistant PDX, with targeted inhibitors being significantly more potent in resistant tumors. Up-regulation of SFKs- and MAPK/ERKpathways was also detected in a sub-group of chemoresistant patients after neoadjuvant treatment. Furthermore, High SFK expression (of either SRC, FYN and/or YES1) was detected in metastatic lesions of TNBC patients with fast progressing disease (median disease-free interval 27 vs 105 months). CONCLUSIONS: Upregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs. Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment. Bulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500). Increased activity in signaling pathways involving SRC-family kinases (SFKs)- and MAPK/ERK was found in treatment resistant PDX, with targeted inhibitors being significantly more potent in resistant tumors. Up-regulation of SFKs- and MAPK/ERK-pathways was also detected in a sub-group of chemoresistant patients after neoadjuvant treatment. Furthermore, High SFK expression (of either SRC, FYN and/or YES1) was detected in metastatic lesions of TNBC patients with fast progressing disease (median disease-free interval 27 vs 105 months). Upregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs. |
Author | Pettersen, Solveig J. Seip, Kotryna Pandya, Abhilash D. Nakken, Sigve Skourti, Eleni Kristian, Alexander Engebraaten, Olav Egeland, Eivind Valen Haugen, Mads H. Prasmickaite, Lina Dahle, Maria A. Øy, Geir Frode Mælandsmo, Gunhild M. |
Author_xml | – sequence: 1 givenname: Eivind Valen orcidid: 0000-0002-7273-7277 surname: Egeland fullname: Egeland, Eivind Valen email: e.v.egeland@ous-research.no organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital – sequence: 2 givenname: Kotryna orcidid: 0000-0001-5936-7294 surname: Seip fullname: Seip, Kotryna organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital – sequence: 3 givenname: Eleni surname: Skourti fullname: Skourti, Eleni organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Insitute for Clinical Medicine, University of Oslo – sequence: 4 givenname: Geir Frode surname: Øy fullname: Øy, Geir Frode organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital – sequence: 5 givenname: Solveig J. surname: Pettersen fullname: Pettersen, Solveig J. organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital – sequence: 6 givenname: Abhilash D. orcidid: 0000-0002-7713-3050 surname: Pandya fullname: Pandya, Abhilash D. organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital – sequence: 7 givenname: Maria A. surname: Dahle fullname: Dahle, Maria A. organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Insitute for Clinical Medicine, University of Oslo – sequence: 8 givenname: Mads H. surname: Haugen fullname: Haugen, Mads H. organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Department of Research and Innovation, Vestre Viken Hospital Trust – sequence: 9 givenname: Alexander surname: Kristian fullname: Kristian, Alexander organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital – sequence: 10 givenname: Sigve orcidid: 0000-0001-8468-2050 surname: Nakken fullname: Nakken, Sigve organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Centre for Bioinformatics, Department of Informatics, University of Oslo – sequence: 11 givenname: Olav surname: Engebraaten fullname: Engebraaten, Olav organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Insitute for Clinical Medicine, University of Oslo, Department of Oncology, Oslo University Hospital – sequence: 12 givenname: Gunhild M. surname: Mælandsmo fullname: Mælandsmo, Gunhild M. organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway-University of Tromsø – sequence: 13 givenname: Lina surname: Prasmickaite fullname: Prasmickaite, Lina organization: Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39390250$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Ul1vFCEUJabGbqt_wAcl8cWXURiGAZ6M2fiVNDHR-kwY5s4OzSxsgdlm_72s01btQxMIIfecc8-Fc4ZOfPCA0EtK3lHC5PvU0Ia2FambsqXgFX-CVpSzuqKyFidoRQgRFVE1OUVnKV2VqyJSPEOnTDFFak5W6OZyBPzzx7oazNZNB5wg7iFhUxbOI0Szgzk7i7OJG8jYeZyj202APWxMdnvAXQSTMrbGW4j4xuURG3s9uwg9jpBcyscKzgHbEbZhET08R08HMyV4cXueo1-fP12uv1YX3798W3-8qGyjVK6oYgZkZxsytFwBpcJw6GWnTC9B9EBl34q2bUwzEGvqjogWasKAcdXRnnXsHH1YdHdzt4Xegs_RTHoX3dbEgw7G6f8r3o16E_aaUs4byWRReL0o2FhmcV77EI2mhDChGResLYi3tz1iuJ4hZb11ycI0GQ9hTpodtQhljSrQNw-gV2GOvrxAQdWtpLUiTUG9-tf0vdu7byuA-s5TSCnCcA-hRB-zoZds6JIN_ScbmheSfECyLpc_DMfB3fQ4lS3UVPr4DcS_th9h_QYReM4o |
CitedBy_id | crossref_primary_10_1186_s12967_024_06047_0 |
Cites_doi | 10.1158/1535-7163.MCT-09-1117 10.1186/s12964-021-00750-x 10.1007/s10549-016-3911-z 10.1038/nrclinonc.2009.129 10.1371/journal.pone.0157368 10.1016/j.molonc.2009.07.003 10.1038/s41467-021-26502-6 10.1016/j.molonc.2012.03.006 10.3389/fonc.2023.1040665 10.1038/ncomms4887 10.1186/s13058-022-01596-y 10.1038/s41598-020-74882-4 10.1371/journal.pone.0279821 10.1038/nrclinonc.2016.66 10.1200/PO.20.00368 10.1016/j.ccr.2009.05.017 10.1016/j.ejmech.2022.114542 10.1158/1078-0432.CCR-14-0432 10.1038/nature23306 10.1093/nar/gkac1000 10.1158/0008-5472.CAN-21-0613 10.1007/s11307-016-0998-x 10.1016/j.ccell.2019.02.001 10.1101/gr.1239303 10.1016/j.phrs.2015.01.003 10.1016/j.tig.2023.02.009 10.1172/JCI45014 10.1186/s13058-016-0690-8 10.1186/s13059-017-1349-1 10.1016/j.clbc.2011.03.021 10.1158/1078-0432.CCR-12-0652 10.1200/JCO.2007.14.4147 10.1158/0008-5472.CAN-13-2175 10.1056/NEJMoa2112651 10.1159/000508759 10.1016/j.clbc.2018.03.010 10.1038/s41571-021-00565-2 10.1093/annonc/mdy024 10.1158/1078-0432.CCR-06-3045 10.1158/1078-0432.CCR-17-0160 10.1056/NEJMoa1910549 10.1016/j.stemcr.2017.03.026 10.1038/s41388-023-02701-x 10.1016/S0140-6736(13)62422-8 10.1038/s41571-022-00682-6 10.1016/j.celrep.2022.110460 10.1038/s43018-022-00337-6 10.1007/978-981-32-9755-5_7 10.3390/cancers14174220 10.1200/PO.20.00086 |
ContentType | Journal Article |
Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. info:eu-repo/semantics/openAccess The Author(s) 2024 2024 |
Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: info:eu-repo/semantics/openAccess – notice: The Author(s) 2024 2024 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U9 H94 K9. NAPCQ 7X8 3HK 5PM |
DOI | 10.1038/s41416-024-02875-5 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic NORA - Norwegian Open Research Archives PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-1827 |
EndPage | 1667 |
ExternalDocumentID | PMC11554838 10037_35736 39390250 10_1038_s41416_024_02875_5 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Kreftforeningen (Norwegian Cancer Society) grantid: 198091; 190257; 190257 funderid: https://doi.org/10.13039/100008730 – fundername: Norges Forskningsråd (Research Council of Norway) grantid: 275437 funderid: https://doi.org/10.13039/501100005416 – fundername: EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) grantid: 847912; 859962 funderid: https://doi.org/10.13039/100010661 – fundername: Funded by the European Project SECRET-ITN within the Horizon 2020 Marie Skłodowska-Curie Grant agreement # 859962 – fundername: Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) grantid: 2021049; 2020072; 2020072; 20240998; 2022069; 2022069 funderid: https://doi.org/10.13039/501100006095 – fundername: EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) grantid: 859962 – fundername: Kreftforeningen (Norwegian Cancer Society) grantid: 190257 – fundername: EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) grantid: 847912 – fundername: Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) grantid: 2020072 – fundername: Kreftforeningen (Norwegian Cancer Society) grantid: 198091 – fundername: Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) grantid: 20240998 – fundername: Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) grantid: 2021049 – fundername: Norges Forskningsråd (Research Council of Norway) grantid: 275437 – fundername: Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) grantid: 2022069 |
GroupedDBID | --- 0R~ 23N 36B 39C 4.4 406 53G 5GY 5RE 6J9 70F 7RV AACDK AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABLJU ABOCM ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BENPR BHPHI BKKNO C6C CS3 DNIVK DPUIP DU5 E3Z EAP EBLON EBS EE. EIOEI EMB F5P FDQFY FEDTE FERAY FIGPU FRJ FSGXE GX1 HCIFZ HVGLF HZ~ IH2 IWAJR JSO JZLTJ KQ8 NQJWS O9- OK1 P2P RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TR2 W2D WH7 ~02 AAFWJ AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION NAPCQ -Q- .55 .GJ 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 8WZ A6W ABAWZ ABDBF ABUWG ACUHS AFKRA AI. AN0 B0M BBNVY BKEYQ BNQBC BPHCQ BVXVI CAG CCPQU CGR COF CUY CVF DIK EAD EAS EBC EBD ECM EIF EJD EMK EMOBN EPL ESX EX3 FIZPM FYUFA HMCUK HYE J5H M1P M41 M7P NPM PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X SV3 TUS UDS UKHRP VH1 WOW X7M Y6R ZGI ~8M 7TO 7U9 H94 K9. 7X8 3HK 3V. AGEZK NAO 5PM |
ID | FETCH-LOGICAL-c499t-193ae8bc40f659e117a5ed8b9ad8e7de18d67664a4f0ca2b076e203e359b1d3b3 |
IEDL.DBID | C6C |
ISSN | 0007-0920 1532-1827 |
IngestDate | Thu Aug 21 18:30:20 EDT 2025 Thu Nov 28 03:21:52 EST 2024 Tue Aug 05 11:03:51 EDT 2025 Thu Jul 17 01:57:10 EDT 2025 Mon Jul 21 05:54:48 EDT 2025 Wed Oct 01 05:02:17 EDT 2025 Thu Apr 24 22:57:28 EDT 2025 Fri Feb 21 02:36:10 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c499t-193ae8bc40f659e117a5ed8b9ad8e7de18d67664a4f0ca2b076e203e359b1d3b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 British Journal of Cancer |
ORCID | 0000-0001-5936-7294 0000-0002-7713-3050 0000-0002-7273-7277 0000-0001-8468-2050 |
OpenAccessLink | https://www.nature.com/articles/s41416-024-02875-5 |
PMID | 39390250 |
PQID | 3126812904 |
PQPubID | 41855 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11554838 cristin_nora_10037_35736 proquest_miscellaneous_3115501349 proquest_journals_3126812904 pubmed_primary_39390250 crossref_primary_10_1038_s41416_024_02875_5 crossref_citationtrail_10_1038_s41416_024_02875_5 springer_journals_10_1038_s41416_024_02875_5 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20241130 |
PublicationDateYYYYMMDD | 2024-11-30 |
PublicationDate_xml | – month: 11 year: 2024 text: 20241130 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | British journal of cancer |
PublicationTitleAbbrev | Br J Cancer |
PublicationTitleAlternate | Br J Cancer |
PublicationYear | 2024 |
Publisher | Nature Publishing Group UK Nature Publishing Group Springer Nature |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Springer Nature |
References | Akbani, Ng, Werner, Shahmoradgoli, Zhang, Ju (CR30) 2014; 5 Aguilera, López-Contreras (CR36) 2023; 39 Chin, Yoshida, Marusyk, Beck, Polyak, Toker (CR52) 2014; 74 CR35 Dent, Trudeau, Pritchard, Hanna, Kahn, Sawka (CR2) 2007; 13 CR32 Zhang, Wang, Gerald, Hudis, Norton, Smid (CR43) 2009; 16 Bianchini, Balko, Mayer, Sanders, Gianni (CR1) 2016; 13 Powell, Redwood, Liu, Guo, Cai, Zhou (CR20) 2020; 10 Aran, Hu, Butte (CR34) 2017; 18 Lehmann, Bauer, Chen, Sanders, Chakravarthy, Shyr (CR9) 2011; 121 Luo, Zou, Guo, Tong, Ye, Zhu (CR38) 2022; 24 Schmid, Cortes, Pusztai, McArthur, Kümmel, Bergh (CR4) 2020; 382 Lehmann, Colaprico, Silva, Chen, An, Ban (CR16) 2021; 12 Masuda, Harano, Miura, Wang, Hirota, Harada (CR17) 2022; 6 Gómez-Miragaya, Palafox, Paré, Yoldi, Ferrer, Vila (CR21) 2017; 8 Bianchini, De Angelis, Licata, Gianni (CR8) 2022; 19 Bareche, Venet, Ignatiadis, Aftimos, Piccart, Rothe (CR11) 2018; 29 Szklarczyk, Kirsch, Koutrouli, Nastou, Mehryary, Hachilif (CR26) 2023; 51 Roskoski (CR37) 2015; 94 Ortiz, Mikhailova, Li, Porter, Bah, Kotula (CR49) 2021; 19 Robinson, Wu, Lonigro, Vats, Cobain, Everett (CR33) 2017; 548 CR42 Jiang, Ma, Suo, Shi, Xue, Hu (CR15) 2019; 35 Morris, Rota, Cadoo, Zamora, Patil, D’Andrea (CR47) 2018; 18 Cortazar, Zhang, Untch, Mehta, Costantino, Wolmark (CR6) 2014; 384 Guillen, Fujita, Butterfield, Scherer, Bailey, Chu (CR19) 2022; 3 Temps, Lietha, Webb, Li, Dawson, Muir (CR50) 2021; 81 Xu, Kumari, Zhou, Chen, Mao, Wang (CR39) 2023; 18 Schmid, Cortes, Dent, Pusztai, McArthur, Kümmel (CR5) 2022; 386 Burstein, Tsimelzon, Poage, Covington, Contreras, Fuqua (CR10) 2015; 21 Liu, Jiang, Xu, Yu, Jin, Hu (CR13) 2016; 18 Poh, Ernst (CR40) 2023; 42 Zanella, Grassi, Trusolino (CR18) 2022; 19 Moulder, Yan, Huang, Hess, Liedtke, Lin (CR48) 2010; 9 Furlanetto, Loibl (CR3) 2020; 15 Pettersen, Øy, Egeland, Juell, Engebråten, Mælandsmo (CR25) 2023; 13 Kim, Song, Haura (CR51) 2009; 6 Lehmann, Jovanović, Chen, Estrada, Johnson, Shyr (CR12) 2016; 11 Silwal-Pandit, Nord, von der Lippe Gythfeldt, Moller, Fleischer, Rodland (CR31) 2017; 23 Liedtke, Mazouni, Hess, André, Tordai, Mejia (CR7) 2008; 26 Gucalp, Sparano, Caravelli, Santamauro, Patil, Abbruzzi (CR44) 2011; 11 Kristian, Holtedahl, Torheim, Futsaether, Hernes, Engebraaten (CR24) 2017; 19 Engle, Kumar (CR41) 2022; 239 Shehwana, Kumar, Melott, Rohrdanz, Wakefield, Ju (CR29) 2022; 38 CR28 Lindholm, Kristian, Nalwoga, Krüger, Nygård, Akslen (CR23) 2012; 6 Shannon, Markiel, Ozier, Baliga, Wang, Ramage (CR27) 2003; 13 Somlo, Atzori, Strauss, Geese, Specht, Gradishar (CR46) 2013; 19 Bergamaschi, Hjortland, Triulzi, Sorlie, Johnsen, Ree (CR22) 2009; 3 Schott, Barlow, Van Poznak, Hayes, Moinpour, Lew (CR45) 2016; 159 Gong, Jiang, Shao, Peng, Liu, Li (CR14) 2022; 38 P Aguilera (2875_CR36) 2023; 39 K Engle (2875_CR41) 2022; 239 2875_CR42 J Gómez-Miragaya (2875_CR21) 2017; 8 KP Guillen (2875_CR19) 2022; 3 AR Poh (2875_CR40) 2023; 42 J Luo (2875_CR38) 2022; 24 XH Zhang (2875_CR43) 2009; 16 BD Lehmann (2875_CR16) 2021; 12 G Bianchini (2875_CR8) 2022; 19 MA Ortiz (2875_CR49) 2021; 19 R Dent (2875_CR2) 2007; 13 R Akbani (2875_CR30) 2014; 5 2875_CR32 TQ Gong (2875_CR14) 2022; 38 YZ Jiang (2875_CR15) 2019; 35 2875_CR35 YR Chin (2875_CR52) 2014; 74 BD Lehmann (2875_CR12) 2016; 11 C Temps (2875_CR50) 2021; 81 P Cortazar (2875_CR6) 2014; 384 R Roskoski Jr (2875_CR37) 2015; 94 A Gucalp (2875_CR44) 2011; 11 G Bianchini (2875_CR1) 2016; 13 PG Morris (2875_CR47) 2018; 18 P Schmid (2875_CR5) 2022; 386 DR Robinson (2875_CR33) 2017; 548 P Schmid (2875_CR4) 2020; 382 ER Zanella (2875_CR18) 2022; 19 P Shannon (2875_CR27) 2003; 13 2875_CR28 D Szklarczyk (2875_CR26) 2023; 51 EM Lindholm (2875_CR23) 2012; 6 A Kristian (2875_CR24) 2017; 19 RT Powell (2875_CR20) 2020; 10 Y Bareche (2875_CR11) 2018; 29 D Aran (2875_CR34) 2017; 18 J Furlanetto (2875_CR3) 2020; 15 C Liedtke (2875_CR7) 2008; 26 MD Burstein (2875_CR10) 2015; 21 L Silwal-Pandit (2875_CR31) 2017; 23 S Pettersen (2875_CR25) 2023; 13 S Moulder (2875_CR48) 2010; 9 YR Liu (2875_CR13) 2016; 18 G Somlo (2875_CR46) 2013; 19 BD Lehmann (2875_CR9) 2011; 121 X Xu (2875_CR39) 2023; 18 H Shehwana (2875_CR29) 2022; 38 H Masuda (2875_CR17) 2022; 6 LC Kim (2875_CR51) 2009; 6 AF Schott (2875_CR45) 2016; 159 A Bergamaschi (2875_CR22) 2009; 3 |
References_xml | – volume: 9 start-page: 1120 year: 2010 end-page: 7 ident: CR48 article-title: Development of candidate genomic markers to select breast cancer patients for dasatinib therapy publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-09-1117 – volume: 19 start-page: 67 year: 2021 ident: CR49 article-title: SRC family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition publication-title: Cell Commun Signal : CCS doi: 10.1186/s12964-021-00750-x – volume: 159 start-page: 87 year: 2016 end-page: 95 ident: CR45 article-title: Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-016-3911-z – volume: 6 start-page: 587 year: 2009 end-page: 95 ident: CR51 article-title: Src kinases as therapeutic targets for cancer publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2009.129 – volume: 11 start-page: e0157368 year: 2016 ident: CR12 article-title: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection publication-title: PLOS ONE doi: 10.1371/journal.pone.0157368 – volume: 3 start-page: 469 year: 2009 end-page: 82 ident: CR22 article-title: Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models publication-title: Mol Oncol doi: 10.1016/j.molonc.2009.07.003 – volume: 12 year: 2021 ident: CR16 article-title: Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes publication-title: Nat Commun doi: 10.1038/s41467-021-26502-6 – volume: 6 start-page: 418 year: 2012 end-page: 27 ident: CR23 article-title: Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts publication-title: Mol Oncol doi: 10.1016/j.molonc.2012.03.006 – volume: 13 year: 2023 ident: CR25 article-title: Breast cancer patient-derived explant cultures recapitulate in vivo drug responses publication-title: Front Oncol doi: 10.3389/fonc.2023.1040665 – volume: 5 year: 2014 ident: CR30 article-title: A pan-cancer proteomic perspective on The Cancer Genome Atlas publication-title: Nat Commun doi: 10.1038/ncomms4887 – ident: CR35 – volume: 24 year: 2022 ident: CR38 article-title: SRC kinase-mediated signaling pathways and targeted therapies in breast cancer publication-title: Breast Cancer Res doi: 10.1186/s13058-022-01596-y – volume: 10 year: 2020 ident: CR20 article-title: Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer publication-title: Sci Rep. doi: 10.1038/s41598-020-74882-4 – volume: 18 start-page: e0279821 year: 2023 ident: CR39 article-title: A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology publication-title: PLoS One doi: 10.1371/journal.pone.0279821 – volume: 13 start-page: 674 year: 2016 end-page: 90 ident: CR1 article-title: Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2016.66 – ident: CR42 – volume: 6 year: 2022 ident: CR17 article-title: Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy publication-title: JCO Precis Oncol doi: 10.1200/PO.20.00368 – volume: 16 start-page: 67 year: 2009 end-page: 78 ident: CR43 article-title: Latent bone metastasis in breast cancer tied to Src-dependent survival signals publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.05.017 – volume: 239 year: 2022 ident: CR41 article-title: Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update publication-title: Eur J medicinal Chem doi: 10.1016/j.ejmech.2022.114542 – volume: 21 start-page: 1688 year: 2015 end-page: 98 ident: CR10 article-title: Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-0432 – volume: 548 start-page: 297 year: 2017 end-page: 303 ident: CR33 article-title: Integrative clinical genomics of metastatic cancer publication-title: Nature doi: 10.1038/nature23306 – volume: 51 start-page: D638 year: 2023 end-page: d46 ident: CR26 article-title: The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest publication-title: Nucleic Acids Res doi: 10.1093/nar/gkac1000 – volume: 81 start-page: 5438 year: 2021 end-page: 50 ident: CR50 article-title: A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-21-0613 – ident: CR32 – volume: 19 start-page: 271 year: 2017 end-page: 9 ident: CR24 article-title: Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts publication-title: Mol Imaging Biol doi: 10.1007/s11307-016-0998-x – volume: 35 start-page: 428 year: 2019 end-page: 40.e5 ident: CR15 article-title: Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.02.001 – volume: 13 start-page: 2498 year: 2003 end-page: 504 ident: CR27 article-title: Cytoscape: a software environment for integrated models of biomolecular interaction networks publication-title: Genome Res doi: 10.1101/gr.1239303 – volume: 94 start-page: 9 year: 2015 end-page: 25 ident: CR37 article-title: Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors publication-title: Pharmacol Res doi: 10.1016/j.phrs.2015.01.003 – volume: 39 start-page: 505 year: 2023 end-page: 19 ident: CR36 article-title: ATRX, a guardian of chromatin publication-title: Trends Genet : TIG doi: 10.1016/j.tig.2023.02.009 – volume: 121 start-page: 2750 year: 2011 end-page: 67 ident: CR9 article-title: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies publication-title: J Clin Invest doi: 10.1172/JCI45014 – volume: 18 year: 2016 ident: CR13 article-title: Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer publication-title: Breast Cancer Res doi: 10.1186/s13058-016-0690-8 – volume: 18 year: 2017 ident: CR34 article-title: xCell: digitally portraying the tissue cellular heterogeneity landscape publication-title: Genome Biol doi: 10.1186/s13059-017-1349-1 – volume: 11 start-page: 306 year: 2011 end-page: 11 ident: CR44 article-title: Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer publication-title: Clin breast cancer doi: 10.1016/j.clbc.2011.03.021 – volume: 19 start-page: 1884 year: 2013 end-page: 93 ident: CR46 article-title: Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-0652 – volume: 26 start-page: 1275 year: 2008 end-page: 81 ident: CR7 article-title: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.4147 – volume: 74 start-page: 964 year: 2014 end-page: 73 ident: CR52 article-title: Targeting Akt3 signaling in triple-negative breast cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-2175 – volume: 386 start-page: 556 year: 2022 end-page: 67 ident: CR5 article-title: Event-free survival with pembrolizumab in early triple-negative breast cancer publication-title: N. Engl J Med doi: 10.1056/NEJMoa2112651 – volume: 15 start-page: 217 year: 2020 end-page: 26 ident: CR3 article-title: Optimal systemic treatment for early triple-negative breast cancer publication-title: Breast care (Basel, Switz) doi: 10.1159/000508759 – volume: 18 start-page: 387 year: 2018 end-page: 94 ident: CR47 article-title: Phase II study of paclitaxel and dasatinib in metastatic breast cancer publication-title: Clin breast cancer doi: 10.1016/j.clbc.2018.03.010 – volume: 19 start-page: 91 year: 2022 end-page: 113 ident: CR8 article-title: Treatment landscape of triple-negative breast cancer — expanded options, evolving needs publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00565-2 – volume: 29 start-page: 895 year: 2018 end-page: 902 ident: CR11 article-title: Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis publication-title: Ann Oncol doi: 10.1093/annonc/mdy024 – volume: 13 start-page: 4429 year: 2007 end-page: 34 ident: CR2 article-title: Triple-negative breast cancer: clinical features and patterns of recurrence publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-3045 – volume: 23 start-page: 4662 year: 2017 end-page: 70 ident: CR31 article-title: The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0160 – volume: 382 start-page: 810 year: 2020 end-page: 21 ident: CR4 article-title: Pembrolizumab for early triple-negative breast cancer publication-title: N. Engl J Med doi: 10.1056/NEJMoa1910549 – volume: 8 start-page: 1392 year: 2017 end-page: 407 ident: CR21 article-title: Resistance to Taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population publication-title: Stem Cell Rep. doi: 10.1016/j.stemcr.2017.03.026 – volume: 42 start-page: 1786 year: 2023 end-page: 801 ident: CR40 article-title: Functional roles of SRC signaling in pancreatic cancer: recent insights provide novel therapeutic opportunities publication-title: Oncogene doi: 10.1038/s41388-023-02701-x – ident: CR28 – volume: 38 start-page: 5131 year: 2022 end-page: 3 ident: CR29 article-title: RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data publication-title: Bioinforma (Oxf, Engl) – volume: 384 start-page: 164 year: 2014 end-page: 72 ident: CR6 article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis publication-title: Lancet doi: 10.1016/S0140-6736(13)62422-8 – volume: 19 start-page: 719 year: 2022 end-page: 32 ident: CR18 article-title: Towards precision oncology with patient-derived xenografts publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-022-00682-6 – volume: 38 year: 2022 ident: CR14 article-title: Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer publication-title: Cell Rep doi: 10.1016/j.celrep.2022.110460 – volume: 3 start-page: 232 year: 2022 end-page: 50 ident: CR19 article-title: A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology publication-title: Nat cancer doi: 10.1038/s43018-022-00337-6 – volume: 5 year: 2014 ident: 2875_CR30 publication-title: Nat Commun doi: 10.1038/ncomms4887 – volume: 19 start-page: 67 year: 2021 ident: 2875_CR49 publication-title: Cell Commun Signal : CCS doi: 10.1186/s12964-021-00750-x – volume: 21 start-page: 1688 year: 2015 ident: 2875_CR10 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-0432 – volume: 548 start-page: 297 year: 2017 ident: 2875_CR33 publication-title: Nature doi: 10.1038/nature23306 – volume: 51 start-page: D638 year: 2023 ident: 2875_CR26 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkac1000 – volume: 18 year: 2017 ident: 2875_CR34 publication-title: Genome Biol doi: 10.1186/s13059-017-1349-1 – volume: 94 start-page: 9 year: 2015 ident: 2875_CR37 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2015.01.003 – volume: 3 start-page: 232 year: 2022 ident: 2875_CR19 publication-title: Nat cancer doi: 10.1038/s43018-022-00337-6 – volume: 121 start-page: 2750 year: 2011 ident: 2875_CR9 publication-title: J Clin Invest doi: 10.1172/JCI45014 – volume: 42 start-page: 1786 year: 2023 ident: 2875_CR40 publication-title: Oncogene doi: 10.1038/s41388-023-02701-x – volume: 10 year: 2020 ident: 2875_CR20 publication-title: Sci Rep. doi: 10.1038/s41598-020-74882-4 – volume: 8 start-page: 1392 year: 2017 ident: 2875_CR21 publication-title: Stem Cell Rep. doi: 10.1016/j.stemcr.2017.03.026 – ident: 2875_CR28 doi: 10.1007/978-981-32-9755-5_7 – volume: 3 start-page: 469 year: 2009 ident: 2875_CR22 publication-title: Mol Oncol doi: 10.1016/j.molonc.2009.07.003 – volume: 19 start-page: 271 year: 2017 ident: 2875_CR24 publication-title: Mol Imaging Biol doi: 10.1007/s11307-016-0998-x – volume: 384 start-page: 164 year: 2014 ident: 2875_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(13)62422-8 – volume: 6 start-page: 418 year: 2012 ident: 2875_CR23 publication-title: Mol Oncol doi: 10.1016/j.molonc.2012.03.006 – volume: 19 start-page: 91 year: 2022 ident: 2875_CR8 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00565-2 – volume: 13 start-page: 674 year: 2016 ident: 2875_CR1 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2016.66 – volume: 29 start-page: 895 year: 2018 ident: 2875_CR11 publication-title: Ann Oncol doi: 10.1093/annonc/mdy024 – volume: 13 start-page: 4429 year: 2007 ident: 2875_CR2 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-3045 – volume: 13 start-page: 2498 year: 2003 ident: 2875_CR27 publication-title: Genome Res doi: 10.1101/gr.1239303 – volume: 9 start-page: 1120 year: 2010 ident: 2875_CR48 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-09-1117 – volume: 18 year: 2016 ident: 2875_CR13 publication-title: Breast Cancer Res doi: 10.1186/s13058-016-0690-8 – volume: 26 start-page: 1275 year: 2008 ident: 2875_CR7 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.4147 – volume: 18 start-page: 387 year: 2018 ident: 2875_CR47 publication-title: Clin breast cancer doi: 10.1016/j.clbc.2018.03.010 – volume: 74 start-page: 964 year: 2014 ident: 2875_CR52 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-2175 – volume: 81 start-page: 5438 year: 2021 ident: 2875_CR50 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-21-0613 – volume: 38 start-page: 5131 year: 2022 ident: 2875_CR29 publication-title: Bioinforma (Oxf, Engl) – volume: 239 year: 2022 ident: 2875_CR41 publication-title: Eur J medicinal Chem doi: 10.1016/j.ejmech.2022.114542 – volume: 38 year: 2022 ident: 2875_CR14 publication-title: Cell Rep doi: 10.1016/j.celrep.2022.110460 – volume: 16 start-page: 67 year: 2009 ident: 2875_CR43 publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.05.017 – volume: 6 start-page: 587 year: 2009 ident: 2875_CR51 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2009.129 – volume: 19 start-page: 1884 year: 2013 ident: 2875_CR46 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-0652 – volume: 386 start-page: 556 year: 2022 ident: 2875_CR5 publication-title: N. Engl J Med doi: 10.1056/NEJMoa2112651 – volume: 11 start-page: 306 year: 2011 ident: 2875_CR44 publication-title: Clin breast cancer doi: 10.1016/j.clbc.2011.03.021 – volume: 19 start-page: 719 year: 2022 ident: 2875_CR18 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-022-00682-6 – volume: 35 start-page: 428 year: 2019 ident: 2875_CR15 publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.02.001 – volume: 24 year: 2022 ident: 2875_CR38 publication-title: Breast Cancer Res doi: 10.1186/s13058-022-01596-y – volume: 23 start-page: 4662 year: 2017 ident: 2875_CR31 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0160 – volume: 159 start-page: 87 year: 2016 ident: 2875_CR45 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-016-3911-z – volume: 13 year: 2023 ident: 2875_CR25 publication-title: Front Oncol doi: 10.3389/fonc.2023.1040665 – volume: 18 start-page: e0279821 year: 2023 ident: 2875_CR39 publication-title: PLoS One doi: 10.1371/journal.pone.0279821 – ident: 2875_CR42 doi: 10.3390/cancers14174220 – volume: 382 start-page: 810 year: 2020 ident: 2875_CR4 publication-title: N. Engl J Med doi: 10.1056/NEJMoa1910549 – volume: 39 start-page: 505 year: 2023 ident: 2875_CR36 publication-title: Trends Genet : TIG doi: 10.1016/j.tig.2023.02.009 – volume: 15 start-page: 217 year: 2020 ident: 2875_CR3 publication-title: Breast care (Basel, Switz) doi: 10.1159/000508759 – volume: 11 start-page: e0157368 year: 2016 ident: 2875_CR12 publication-title: PLOS ONE doi: 10.1371/journal.pone.0157368 – volume: 12 year: 2021 ident: 2875_CR16 publication-title: Nat Commun doi: 10.1038/s41467-021-26502-6 – volume: 6 year: 2022 ident: 2875_CR17 publication-title: JCO Precis Oncol doi: 10.1200/PO.20.00368 – ident: 2875_CR32 doi: 10.1200/PO.20.00086 – ident: 2875_CR35 |
SSID | ssj0009087 |
Score | 2.4967794 |
Snippet | Background
Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of... Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple... BackgroundResistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of... BACKGROUND: Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of... |
SourceID | pubmedcentral cristin proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1656 |
SubjectTerms | 631/67/1059 631/67/1347 631/67/1857 631/67/70 Animals Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Cancer therapies Chemotherapy Disease management Drug Resistance Drug Resistance, Neoplasm Epidemiology Explants Female Fyn protein Humans Kinases MAP kinase MAP Kinase Signaling System - drug effects Metastases Metastasis Mice Molecular Medicine Oncology Paclitaxel Paclitaxel - pharmacology Paclitaxel - therapeutic use Patients Protein arrays Signal transduction Signal Transduction - drug effects Src protein src-Family Kinases - antagonists & inhibitors src-Family Kinases - metabolism Therapeutic targets Treatment resistance Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology Tumors Up-regulation Xenograft Model Antitumor Assays |
Title | The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy |
URI | https://link.springer.com/article/10.1038/s41416-024-02875-5 https://www.ncbi.nlm.nih.gov/pubmed/39390250 https://www.proquest.com/docview/3126812904 https://www.proquest.com/docview/3115501349 http://hdl.handle.net/10037/35736 https://pubmed.ncbi.nlm.nih.gov/PMC11554838 |
Volume | 131 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1532-1827 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: KQ8 dateStart: 19990101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1532-1827 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: KQ8 dateStart: 19470101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1532-1827 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: GX1 dateStart: 19470101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1532-1827 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VVkJcEO8GSmUkbmDhVxzn2K5YVUjtAajUmxU7DlSCLNpNhfj3zDjZLUsBCSk52XEczzj-5uHPAC9Fi4its5q7KEtu0ODgjexqjsg1yqDoVBEyFE_P7Mm5eXdRXuyAWu-FyUn7mdIy_6bX2WFvVkYidOC4ouCNGJuXt2DPVVpSGt_Mzq6JdoUbeTLJBVcrMW2UEdr9oQ0EvTHPpX57WbqBNW-mTP4WN83L0fwe3J1wJDsae34fdlL_AG6fTpHyh_Ad5c8-vJ_x0YPByPmaVqzBi_2y54qNmeDssmfDknzurE-fMhc4C5SuPrBIarFk5K9lTaS84dQytNEJd2IJGxYM5f512sj14xGcz99-nJ3w6ZAFHtHYGTgCuCa5EI3obFknKaumTK0LddO6VLVJutZW1prGdCI2KojKJiV00mUdZKuDfgy7_aJP-8BChy1iQ8EkZaxqg2tLFZNLznZVl1QB-9No-x71m-iSdeV1WWlbgFwPv48TOTmdkfHF5yC5dn4Unkfh-Sw8XxbwavPMt5Ga45-1D9ZS9dM0XXktFfGv1cIU8GJTjBOMoiZNnxZXVIesOGJxLODJqASb1-laU5hWFOC21GNTgci7t0v6y8-ZxJtaNU67Al6vNem6X3__jKf_V_0Z3FGk75mr8gB2h-VVeo4oagiHsHc0Pz4-O8zT5yf7ShWs |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VIgEXxLuBAkbiBhZ-JI5zRCuqBbo9QCv1ZsWOA5Ugi3ZTIf49M06yZSkgISUnO47jGcffPPwZ4LloELG1RnMbZMFzNDh4LduKI3IN0is6VYQMxcWRmZ_k706L0x1Q016YlLSfKC3Tb3rKDnu1ziVCB44rCt6IsXlxBa5aXP7I4JqZ2QXRrrADTya54Colxo0yQts_tIGgN6S51G0vS5ew5uWUyd_ipmk5OrgFN0ccyV4PPb8NO7G7A9cWY6T8LnxH-bOPH2Z88GAwcr7GNavxYr_suWJDJjg761i_Ip876-KnxAXOPKWr9yyQWqwY-WtZHShvODYMbXTCnVjC-iVDuX8dN3L9uAcnB2-OZ3M-HrLAAxo7PUcAV0frQy5aU1RRyrIuYmN9VTc2lk2UtjGlMXmdtyLUyovSRCV01EXlZaO9vg-73bKLe8B8iy1iQz6PKjeq8bYpVIg2WtOWbVQZ7I2j7TrUb6JL1qXTRalNBnIafhdGcnI6I-OLS0Fybd0gPIfCc0l4rsjgxeaZbwM1xz9r709SdeM0XTstFfGvVSLP4NmmGCcYRU3qLi7PqQ5ZccTimMGDQQk2r9OVpjCtyMBuqcemApF3b5d0Z58TiTe1mlttM3g5adJFv_7-GQ__r_pTuD4_Xhy6w7dH7x_BDUW6n3gr92G3X53Hx4ioev8kTaGfeAIXHw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwEB6VIlW8IO4GChiJNzA4seM4j2hhVY5WCKjUNys-ApUgW-2mQvx7Zpxky1JAQkqe7DjHzMTfHP4M8FgERGytltz4vOQKHQ7e5G3NEbn63BW0qwg5igeHev9IvTkuj7dAT2thUtF-orRMv-mpOuz5SuUIHTjOKHgixubls9PQXoLLpkIToSStnp2T7QozcGVSGK4uxLhYRkjzh3EQ-PpkT93m1HQBb14sm_wtd5qmpPk1uDpiSfZiePrrsBW7G7BzMGbLb8J31AH28cOMD1EMRgHYuGINHuyXdVdsqAZnJx3rlxR3Z138nPjAmaOS9Z55Uo0lo5gtazzVDsfA0E8n7IktrF8wlP23cTHXj1twNH_1abbPx40WuEeHp-cI4pponFei1WUd87xqyhiMq5tgYhViboKutFaNaoVvCicqHQshoyxrlwfp5G3Y7hZd3AXmWhwRB3IqFkoXwZlQFj6aaHRbtbHIYHf82rZDHSfKZFlZWVZSZ5BPn9_6kaCc9sn4alOiXBo7CM-i8GwSni0zeLK-5nSg5_hn771JqnY01ZWVeUEcbLVQGTxaN6ORUeak6eLijPqQJ0dMjhncGZRgfTtZS0rVigzMhnqsOxCB92ZLd_IlEXnTqMpIk8HTSZPOn-vvr3H3_7o_hJ33L-f23evDt_fgSkGqn6gr92C7X57F-wiqevcgWdBPij4YMQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+SRC-family+serves+as+a+therapeutic+target+in+triple+negative+breast+cancer+with+acquired+resistance+to+chemotherapy&rft.jtitle=British+journal+of+cancer&rft.au=Egeland%2C+Eivind+Valen&rft.au=Seip%2C+Kotryna&rft.au=Skourti%2C+Eleni&rft.au=%C3%98y%2C+Geir+Frode&rft.date=2024-11-30&rft.eissn=1532-1827&rft.volume=131&rft.issue=10&rft.spage=1656&rft_id=info:doi/10.1038%2Fs41416-024-02875-5&rft_id=info%3Apmid%2F39390250&rft.externalDocID=39390250 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |